Adagrasib: First Approval

2023/02/01 by Sohita Dhillon · 26 citations
Medicine · #Lung Cancer Treatments and Mutations #Colorectal Cancer Treatments and Studies #Cancer-related Molecular Pathways

paper · doi:10.1007/s40265-023-01839-y

Cited by

• Electrophilic fragment screening using native mass spectrometry to identify covalent probes for surface cysteines
• Recent Advances in Covalent Drug Discovery. [europepmc]
• Targeting Ras with protein engineering. [europepmc]
• Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. [europepmc]
• Synthesis and clinical application of new drugs approved by FDA in 2022. [europepmc]
• Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges. [europepmc]
• Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. [europepmc]
• A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement. [europepmc]
• If it's a target, it's a pan-cancer target: Tissue is not the issue. [europepmc]
• Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems. [europepmc]
• Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study. [europepmc]
• Integrated molecular profiling of RAS , BRAF mutations, and mismatch repair status in advanced colorectal carcinoma: insights from gender and tumor laterality. [europepmc]
• Preclinical evaluation of targeted therapies for central nervous system metastases. [europepmc]
• KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF‑β mediated epithelial‑mesenchymal transition. [europepmc]
• New insights into protein-protein interaction modulators in drug discovery and therapeutic advance. [europepmc]
• First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives. [europepmc]
• Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. [europepmc]
• Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance. [europepmc]
• Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer. [europepmc]
• SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS G12D inhibitor in KRAS LUAD. [europepmc]
• Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials. [europepmc]
• Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations. [europepmc]
• Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. [europepmc]
• RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236). [europepmc]
• Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. [europepmc]
• Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles. [europepmc]